Hiv Infection Clinical Trials 2023

Browse 99 Hiv Infection Medical Studies Across 153 Cities

23 Phase 3 Trial · 734 Hiv Infection Clinics

Reviewed by Michael Gill, B. Sc.
10 Hiv Infection Clinical Trials Near Me
Top Hospitals for Hiv Infection Clinical Trials
Image of GSK Investigational Site in California.
GSK Investigational Site
Los Angeles
6Active Trials
54All Time Trials for Hiv Infection
2002First Hiv Infection Trial
Image of Alabama CRS in Alabama.
Alabama CRS
Birmingham
6Active Trials
40All Time Trials for Hiv Infection
2009First Hiv Infection Trial
Image of GSK Investigational Site in District of Columbia.
GSK Investigational Site
Washington
5Active Trials
45All Time Trials for Hiv Infection
2002First Hiv Infection Trial
Image of GSK Investigational Site in Texas.
GSK Investigational Site
Dallas
5Active Trials
55All Time Trials for Hiv Infection
2002First Hiv Infection Trial
Image of GSK Investigational Site in Ontario.
GSK Investigational Site
Ottawa
5Active Trials
22All Time Trials for Hiv Infection
2002First Hiv Infection Trial
Top Cities for Hiv Infection Clinical Trials
Image of New York in New York.
New York
44Active Trials
GSK Investigational SiteTop Active Site
Image of San Francisco in California.
San Francisco
28Active Trials
GSK Investigational SiteTop Active Site
Hiv Infection Clinical Trials by Phase of TrialHiv Infection Clinical Trials by Age Group
< 18 Hiv Infection Clinical Trials
4Active Hiv Infection Clinical Trials
Most Recent Hiv Infection Clinical TrialsTop Treatments for Hiv Infection Clinical Trials
Treatment Name
Active Hiv Infection Clinical Trials
All Time Trials for Hiv Infection
First Recorded Hiv Infection Trial
Treatment
29
29
1999
Group 3
1
1
2023
Participants requesting test(s) for HIV, HCV, and/or syphilis
1
1
2022
env (A,B,C,A/E)/gag (C) DNA Vaccine
1
2
2018
Cepheid GeneXpert HIV-1 Qual POC HIV VL test
1
1
2021
Recently Completed Studies with FDA Approved Treatments for Hiv Infection
Treatment
Year
Sponsor
DRV/COBI FDC
2022
Janssen Research & Development, LLC
VH4011499
2022
ViiV Healthcare
VH3810109
2022
ViiV Healthcare
VRC07-523LS (20mg/kg, IV)
2021
National Institute of Allergy and Infectious Diseases (NIAID)
Tenofovir Douche
2021
Johns Hopkins University
JULUCA 50Mg-25Mg Tablet
2021
Indiana University
ABBV-382
2021
AbbVie
N-803
2021
University of Minnesota
Tenofovir Douche
2021
University of Pennsylvania
Budigalimab
2021
AbbVie

What Are HIV infection Clinical Trials?

The virus known as HIV targets the immune system of the human body. If left untreated, HIV can lead to AIDS. Scientists have not yet found an effective cure for HIV. Individuals who contract HIV are permanently infected.

However, people living with HIV can manage the disease with the proper medical treatment. HIV infection clinical trials can help in the management of symptoms, the search for potential treatments, and the development of HIV preventive strategies.

Why Is HIV Infection Being Studied Through Clinical Trials?

By the conclusion of 2021, approximately 38.4 million individuals worldwide were declared HIV positive. According to estimates, 0.7% of individuals in the globe between the ages of 15 to 49 have HIV. At the same time, the severity of the disease continues to differ greatly between different areas worldwide.

HIV infection clinical trials can aid in the discovery of potential prevention strategies to lower the rising number of HIV-positive and HIV-infected individuals. It can also help in the discovery of potential therapies to aid in the better management of symptoms.

What Are The Types Of Treatments Available For HIV Infection?

Individuals with HIV must live with the illness for the rest of their lives because there is no known cure. However, several drugs help manage HIV and avoid side effects. Antiretroviral treatment is the name given to these drugs. Regardless of the stage, doctors immediately start people diagnosed with HIV on Antiretroviral therapy.

ART often consists of a combination of drugs from several pharmacological classes together. This is the most effective treatment for reducing HIV in the bloodstream. Many ART regimens consist of a single daily tablet containing several HIV medicines. Here are two common Antiretroviral treatments for HIV:

Cabotegravir

Antiretroviral medicine cabotegravir, marketed underneath the trade name Vocabria is used by doctors to treat HIV. It comes in the form of intramuscular injections and tablets.

Temixys

Temixys is used to treat HIV-1 infection in children and adults who weigh at least 35 kg. The medication is often prescribed along with other antiretroviral medications.

What Are Some Recent Breakthrough Clinical Trials for HIV infection?

In recent years, there have been several notable HIV infection clinical trials. Some of the breakthrough HIV infection clinical trials are:

2017: Trial of Long-Acting Injectable Medicine for HIV Prevention- This study investigates a long-acting injectable drug for preventing HIV in sexually active females. The experimental anti-HIV medicine cabotegravir, administered intravenously once every eight weeks, is being studied in eastern and southern African regions to see if it may effectively safeguard women susceptible to contracting HIV.

2023: Progress toward HIV cure- This study demonstrates how experimental drugs have the potential to enhance the body's natural capacity to inhibit HIV. According to experts, it is a significant leap toward a cure.

Who Are Some of The Key Opinion Leaders / Researchers in HIV infection Clinical Trial Research?

University Of California San Francisco

UCSF collects high amounts of NIH research funding and funds for HIV/AIDS investigation. The organization contributes to several current studies aimed at HIV prevention and potential cure research.

John Hopkins Medicine

John Hopkins Medicine has employed several HIV researchers carrying out ongoing clinical trials and research aiming to advance HIV/AIDS treatment, management, and diagnosis of HIV.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 28th, 2021

Last Reviewed: September 10th, 2023

References1 Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallás EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010 Dec 30;363(27):2587-99. doi: 10.1056/NEJMoa1011205. Epub 2010 Nov 23. https://pubmed.ncbi.nlm.nih.gov/210912792 Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapia M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernandez T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallas EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV; iPrEx Study Team. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010 Dec 30;363(27):2587-99. doi: 10.1056/NEJMoa1011205. Epub 2010 Nov 23. https://pubmed.ncbi.nlm.nih.gov/210912793 Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, Chiamwongpaet S, Kitisin P, Natrujirote P, Kittimunkong S, Chuachoowong R, Gvetadze RJ, McNicholl JM, Paxton LA, Curlin ME, Hendrix CW, Vanichseni S; Bangkok Tenofovir Study Group. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013 Jun 15;381(9883):2083-90. doi: 10.1016/S0140-6736(13)61127-7. Epub 2013 Jun 13. https://pubmed.ncbi.nlm.nih.gov/237692344 Watson D, Clark LA, Tellegen A. Development and validation of brief measures of positive and negative affect: the PANAS scales. J Pers Soc Psychol. 1988 Jun;54(6):1063-70. doi: 10.1037//0022-3514.54.6.1063. https://pubmed.ncbi.nlm.nih.gov/33978655 Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JH, Godbole SV, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Cottle L, Zhang XC, Makhema J, Mills LA, Panchia R, Faesen S, Eron J, Gallant J, Havlir D, Swindells S, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano DD, Essex M, Hudelson SE, Redd AD, Fleming TR; HPTN 052 Study Team. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med. 2016 Sep 1;375(9):830-9. doi: 10.1056/NEJMoa1600693. Epub 2016 Jul 18. https://pubmed.ncbi.nlm.nih.gov/274248126 Azar MM, Springer SA, Meyer JP, Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend. 2010 Dec 1;112(3):178-93. doi: 10.1016/j.drugalcdep.2010.06.014. Epub 2010 Aug 11. Review. https://pubmed.ncbi.nlm.nih.gov/207054027 Giordano TP, Visnegarwala F, White AC Jr, Troisi CL, Frankowski RF, Hartman CM, Grimes RM. Patients referred to an urban HIV clinic frequently fail to establish care: factors predicting failure. AIDS Care. 2005 Aug;17(6):773-83. doi: 10.1080/09540120412331336652. https://pubmed.ncbi.nlm.nih.gov/160362648 Paz K, Massey KP. Health Disparity among Latina Women: Comparison with Non-Latina Women. Clin Med Insights Womens Health. 2016 Jul 20;9(Suppl 1):71-4. doi: 10.4137/CMWH.S38488. eCollection 2016. https://pubmed.ncbi.nlm.nih.gov/274783939 Azar MM, Springer SA, Meyer JP, Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend. 2010 Dec 1;112(3):178-93. doi: 10.1016/j.drugalcdep.2010.06.014. Epub 2010 Aug 11. https://pubmed.ncbi.nlm.nih.gov/2070540210 Azar MM, Springer SA, Meyer JP, Altice FL. A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend. 2010 Dec 1;112(3):178-93. doi: 10.1016/j.drugalcdep.2010.06.014. Epub 2010 Aug 11. Review. https://pubmed.ncbi.nlm.nih.gov/20705402